Serving leading biopharmaceutical companies globally:

Mallinckrodt
US Department of Justice
Fish and Richardson
Medtronic
McKinsey
AstraZeneca
Moodys
Argus Health
McKesson
Chubb

Which pharmaceutical companies have the most SPCs in Switzerland?

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Switzerland.

SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long time needed to obtain regulatory approval for drugs. SPCs come into force only after the corresponding general patent expires, and normally have a maximum lifetime of 5 years.

The total combined duration of market exclusivity of a general patent and SPC cannot normally exceed 15 years, but a six-month extention may be obtained by responding to a request for pediatric trials.

For a different perspective, see the drug companies with SPCs in the most countries

The pharma companies with the most SPCs in Switzerland are:

Back to Pharmaceutical Industry Infographics

For more information try a trial or see the database preview and plans and pricing

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot